This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 'Dogs of the Dow' to Stomp the Market

Stocks in this article: GE INTC MRK T VCX

Merck

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2013 has been a pretty quiet year for Merck ( MRK). Shares of the big pharma firm have only managed to climb 15% since the start of the year, a pretty decent number for most sectors, but one that falls flat compared to the stellar returns of the rest of the pharmaceutical space. Still, with a dividend payout of 3.55%, Merck makes our list of Dow Dogs worth watching this quarter.

>>5 Stocks With Big Insider Buying

Merck is a $140 billion pharmaceutical firm with a portfolio of well-known drug names that includes Gardasil, Claritin, and Zocor. Singulair has long been Merck's crown jewel, but the firm lost patent protection in the middle of last year, opening the field to generic competition. To fight off the threat of patent drop-offs and cut costs, Merck acquired Schering Plough in 2009, adding an attractive drug pipeline to its existing development efforts. Those new products hold a strong shot at undoing the revenue losses from Singular and other expiring patents.

Like Intel, Merck currently sports a strong balance sheet with plenty of liquidity - more than enough to cover dividend payouts and continue investing in research and development for new drugs. Keep an eye on earnings slated for Oct. 28.

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs